$KFY

Korn/Ferry International (NYSE:KFY) Given New $75.00 Price Target at UBS Group

UBS Group raised its price target for Korn/Ferry International (KFY) to $75 from $70 and kept a “neutral” rating, implying about 4.21% upside from the current price, according to a Wednesday research note cited by Benzinga. Other analysts also adjusted targets. KFY last reported Q2 EPS of $1.40 vs $1.37 consensus on revenue of $768.26M.

Original reporting
Published Jun 24, 2026, 3:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 24, 2026, 3:22 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Korn/Ferry International (NYSE:KFY) Given New $75.00 Price Target at UBS Group — source image
Decision brief

The 30-second read

$KFYBullishLow
01

Why it matters

For traders, the actionable element is the incremental PT change; however, without a rating upgrade or new fundamental disclosure, it is more sentiment/positioning than a catalyst.

02

Market read

KFY receives a modest bullish nudge from a higher PT, but the neutral stance suggests limited conviction.

03

What to watch

The article cites prior earnings and guidance, but does not connect the UBS target change to any new KPI, contract win, or margin trajectory—so traders may discount it.

Relevance 4/10Novelty 4/10Timing: after-hours/next-session positioning following UBS’s Wednesday note

Background

The piece reports a UBS research note that raised Korn/Ferry’s price objective and summarizes other recent analyst rating/target changes.

Company-level read

Ticker impact

$KFYBullishMedium confidence
Context

UBS raised its Korn/Ferry price target to $75 from $70 while keeping a “neutral” rating, implying ~4.2% upside from the article’s reference price.

Expected impact

Likely limited, incremental support for KFY versus a full re-rating; follow-through depends on whether other firms’ views converge.

Evidence & confidence

The only new, company-specific datapoint here is the UBS target raise; rating remains neutral, and the article does not introduce new fundamentals beyond previously referenced earnings/guidance.

Market effects

Small read-through to business services/executive search sentiment, but no sector-wide catalyst is disclosed.

No specific regional macro or policy linkage is provided.

No global deal/regulatory development tied to the firm is mentioned.

Counterpoint

A higher price target with an unchanged “neutral” rating may reflect valuation adjustment rather than improved earnings power, limiting incremental demand.

Key entities

  • Korn/Ferry International

    Business services provider; UBS raised its price target to $75 while keeping a neutral rating.

  • UBS Group

    Issued the Wednesday research note raising the target from $70 to $75.

Related articles

$KFYMed

KORN FERRY (KFY): Results of Operations and Financial Condition

KORN FERRY (KFY) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 kfy-20260430xex991q4fy26.htm EX-99.1 Document Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investor Relations: Tiffany Louder, (214) 310-8407 Media: Dan Gugler, (310) 226-2645 Korn Ferry Announces Fourth Quarter and Full Year FY'26 Results of Operations Fourth Quarter a

$AHRMed

American Healthcare REIT Continues ‘Next Level of Growth’ With SHOP Deals

American Healthcare REIT (AHR) raised its projected investment pipeline to $800 million from $650 million (May). In Q2, it completed $126.9 million of SHOP investments, taking yearly SHOP investments to $1.4 billion. Same-store SHOP NOI grew 20.5% y/y. AHR also reported a $197.5 million in-process development and expansion pipeline, with $72 million funded, and its stock rose 3.71% to $56.74.

$PZZAMed

Papa John’s rules out near-term sale as turnaround takes centre stage

Papa John’s (NASDAQ:PZZA) said it will not pursue a near-term sale and instead focus on its internal turnaround after ending an 18-month strategic review, despite reported takeover interest from Irth Capital Management. Q2 2026 revenue fell to $482.4M, North America comps declined 8.3%, adjusted EBITDA was $52.7M, and EPS was $0.24. The board suspended the dividend and guided FY2026 adjusted EBITDA to $180M-$190M.

$RTXMedAI 9/10

Raytheon wins $1.3 billion in missile defense contracts

Raytheon, according to the U.S. Department of Defense, won two missile-defense related contracts totaling $1.3 billion. It received $745.4 million for Standard Missile-3 Block IIA rounds and $536 million to modify the TOW Weapon System contract, raising its cumulative value to $750.8 million. Work is set in Tucson and Huntsville, with completion dates through 2031.